Positive celiac blood test but a normal biopsy: what doctors call potential celiac disease
Short answer
Positive celiac antibodies with a normal small-bowel biopsy do not by themselves confirm celiac disease4; for adults with persistently positive anti-TG2 and Marsh 0–I histology, the ESsCD says a definitive diagnosis cannot be established5. The guidelines describe these possibilities1, 2, 3:
- Potential celiac disease: positive antibodies with normal small intestinal mucosa in someone at increased risk of developing celiac disease1.
- A false-positive antibody result, which the European Society for the Study of Coeliac Disease (ESsCD) says can occur with conditions such as autoimmune diseases, chronic liver disease and enteric infections2.
- A false-negative biopsy, which the ESsCD says can result from taking too few biopsies3.
Part of Celiac diagnosis, testing and gluten sensitivity, 25 guides

Key points
- Antibodies strongly support a celiac diagnosis but by themselves are not confirmatory, according to the Oslo definitions4.
- For adults with persistently positive anti-TG2 and architecturally normal duodenal histology (Marsh 0–I), the ESsCD says a definitive diagnosis cannot be established; with HLA-DQ2 or DQ8 the person may be classified as having potential celiac disease5.
- The ESsCD describes potential celiac disease as a condition that may remain stable, regress or progress to overt celiac disease6.
- In a meta-analysis of 17 studies, 33% of people with potential celiac disease on a gluten-containing diet developed villous atrophy and 33% had normalised serology7, 8.
- NIDDK says doctors don’t recommend starting a gluten-free diet before diagnostic testing, because the diet can affect test results9.
What “potential celiac disease” means
The Oslo definitions of celiac disease terms recommend using “potential celiac disease” for individuals with normal small intestinal mucosa who are at increased risk of developing celiac disease, as indicated by positive celiac serology1. In the Oslo scheme, a person with positive tTG or EMA antibodies on at least two occasions is classified after a biopsy as celiac disease (positive biopsy) or potential celiac disease (negative biopsy)10.
The same report says these antibodies strongly support the diagnosis but by themselves are not confirmatory4. The American College of Gastroenterology’s guideline abstract describes antibody detection as very helpful for initial screening and says an intestinal biopsy is required in most patients to confirm the diagnosis11.
| Source | How it describes the finding |
|---|---|
| Oslo definitions | Normal small intestinal mucosa in individuals at increased risk of developing celiac disease, as indicated by positive serology1 |
| ESsCD 2025 guideline (adults) | Persistently positive IgA anti-TG2 with architecturally normal duodenal histology (Marsh 0–I): a definitive diagnosis cannot be established, but with HLA-DQ2 and/or DQ8 the person may be classified as having potential celiac disease5 |
| Coeliac UK | Repeatedly high antibody tests, the HLA genetics associated with celiac disease, normal or minimal changes to the gut lining (Marsh 0 and 1), and other conditions ruled out12 |
| ESPGHAN 2020 guidelines (children), abstract | No or mild histological changes (Marsh 0/I) with confirmed autoimmunity (TGA-IgA/EMA-IgA positive): to be followed closely13 |
The wording differs. Oslo’s definition rests on serology and a biopsy with normal mucosa1; the ESsCD and Coeliac UK also name HLA-DQ2/DQ8 genetics5, 12, and the ESsCD, Coeliac UK and ESPGHAN include Marsh 0–I rather than only a normal biopsy5, 12, 13.
Oslo also discourages the older term “latent celiac disease” for this situation, because “latent” and “potential” have often been used interchangeably, resulting in confusion14.
Why antibodies and a biopsy can disagree
The ESsCD says potential celiac disease should be differentiated from other conditions that lead to mild, transient elevations in celiac serology or to lymphocytic duodenitis (Marsh I)15. It adds that these alternative causes must be thoroughly excluded before a diagnosis of potential celiac disease is confirmed15.
The antibody result may be a false positive
The ESsCD says false-positive celiac serology can be seen with hypergammaglobulinemia, autoimmune diseases, chronic liver disease and enteric infections, and that transient positive anti-TG2 antibodies may be seen at the time of type 1 diabetes diagnosis2.
The biopsy may have missed damage
The ESsCD says false-negative biopsies can result from taking too few biopsies3. It states that it is generally believed celiac lesions may have a patchy distribution16, and it recommends at least four biopsies from the distal duodenum plus two from the duodenal bulb17. It adds that bulb biopsies may improve detection of early or localised involvement18.
The British Society of Gastroenterology, as reported by Coeliac UK, advises at least two biopsies from the duodenal bulb and four from the second part of the duodenum, placed in separate pathology pots19. Oslo names variability in the adequacy of the biopsies taken as a difficulty in defining the potential group20.
The ESsCD also says a pathology report should state the number of biopsies received, the quality of orientation, the Vi:Cr ratio (villous height to crypt depth), the intraepithelial lymphocyte (IEL) count and the Marsh stage21.
What the guidelines describe as next steps
These documents describe what specialists are asked to consider. They are not advice for one person; whether any of it applies is for that person’s own clinician.
| Source | Who it covers | What it describes |
|---|---|---|
| ESsCD 2025 | Adults | Suggests repeating the IgA anti-TG2 test to rule out a false-positive or transient result, with enough gluten eaten before the repeat test22; making sure enough biopsies are collected23; and consulting a celiac specialist for complex cases and a review of the biopsies for subtle abnormalities24. |
| ESsCD 2025 | Adults with persistent symptoms | Says to consider repeating serology in 3–6 months while continuing an unrestricted gluten intake if tolerated, and, if that is not tolerated, a gluten-free diet supervised by a dietitian25. |
| ESsCD 2025 | Adults without symptoms | Says the gluten-containing diet can be continued, with clinical and endoscopic follow-up recommended, as one-third may progress to celiac disease or show seroconversion26. |
| ESsCD 2025 | Adults with strong clinical suspicion | Says further work-up, including immunohistochemistry, repeat endoscopy or a second pathology review, may be considered case by case27. |
| Coeliac UK, reporting British Society of Gastroenterology advice | Adults who keep eating gluten | The BSG advises discussing repeat serology and biopsies 1–2 years after diagnosis or if new symptoms develop28. Coeliac UK says such a person should be made aware of their risk of developing celiac disease29. |
| Coeliac UK | People with symptoms | The guidelines suggest a gluten-free diet could be trialled with the support of a specialist dietitian, and reconsidered if there is no improvement after around 3–6 months30. Follow-up for those who adopt the diet should be the same as for diagnosed celiac disease31. |
| ESPGHAN 2020, abstract | Children | Discordant antibody and biopsy results may require re-evaluation of the biopsies; Marsh 0/I changes with confirmed autoimmunity should be followed closely13. |
The timing differs by group: the ESsCD gives 3–6 months for repeat serology in adults with persistent symptoms25, while Coeliac UK gives 1–2 years for repeat testing in people who stay on gluten and remain stable29. Coeliac UK also describes potential celiac disease as often considered an early manifestation of celiac disease32.
What follow-up studies found
Three published studies are summarized here from their abstracts. They differ in design and population, so their figures are shown side by side and not combined.
| Study | Who | Follow-up | What the abstract reports |
|---|---|---|---|
| Meta-analysis in Gut, 2024 (Shiha et al.) | 17 studies of 1010 people with potential celiac disease; pooled prevalence among people with suspected celiac disease 16%7 | Most studies at least 1 year; within studies, 5 months to 13 years33 | On a gluten-containing diet, 33% (95% CI 18% to 48%) developed villous atrophy and 33% (95% CI 17% to 48%) had normalisation of serology8 |
| Gastroenterology, 2019 (Auricchio et al.) | 280 children in Italy with suspected celiac disease34 | Up to 12 years, median 60 months34 | 42 (15%) developed villous atrophy and 89 (32%) no longer tested positive for anti-TG2 or anti-EMA; cumulative incidence of villous atrophy 43% at 12 years35 |
| Clinical Gastroenterology and Hepatology, 2016 (Volta et al.) | 77 adults diagnosed with potential celiac disease at Bologna University36 | 3 years37 | Of 16 asymptomatic patients who kept eating gluten, 1 developed mucosal flattening and antibody levels fluctuated in 5 or became undetectable38; all 61 symptomatic patients showed significant clinical improvement after gluten withdrawal39 |
The interval around the meta-analysis’s villous-atrophy figure is wide, 18% to 48%8. Among people in those studies who adhered to a gluten-free diet, 88% (95% CI 79% to 97%) reported symptomatic improvement8. The authors write that their findings highlight the importance of structured follow-up and individualised management40.
Why guidelines keep gluten in the diet until testing is finished
NIDDK says doctors don’t recommend starting a gluten-free diet before diagnostic testing, because the diet can affect test results9. Coeliac UK says it is important to continue eating gluten until all the required tests, blood tests and biopsy where necessary, are done, and that reducing gluten before testing will affect results41. It reports that guidelines recommend eating some gluten in more than one meal every day for at least six weeks before testing42.
The ESsCD makes the same point about antibody tests: insufficient gluten intake, for example when someone starts a gluten-free diet on their own and there is a delay before endoscopy, may give a negative serology result43. The ESsCD describes two routes: a dietitian-supervised gluten-free diet for people with persistent symptoms who cannot tolerate unrestricted gluten25, and continued gluten with follow-up for people without symptoms26. Which applies to a given person is for that person’s clinician.
Related guides below cover what a gluten challenge involves, what tTG-IgA numbers mean and how a biopsy report is read.
Questions people ask
Can someone have celiac disease with a normal biopsy?
The ESsCD says that with persistently positive anti-TG2 and architecturally normal duodenal histology, a definitive diagnosis cannot be established, and the person may be classified as having potential celiac disease if they carry HLA-DQ2 and/or DQ85. Oslo says antibodies strongly support the diagnosis but by themselves are not confirmatory4.
Is potential celiac disease the same as latent celiac disease?
Oslo says the two terms have often been used interchangeably, resulting in confusion, and discourages the use of “latent”14.
Does a normal biopsy mean the antibody test was wrong?
Not necessarily. The ESsCD lists false-positive serology as one explanation to rule out, with a repeat antibody test as part of its suggested approach2, 22. It also says too few biopsies can produce a false-negative result3.
Will potential celiac disease turn into celiac disease?
In one meta-analysis, 33% of people with potential celiac disease on a gluten-containing diet developed villous atrophy, and 33% had normalisation of serology8. The ESsCD describes the condition as one that may remain stable, regress or progress to overt celiac disease6.
Is a repeat biopsy part of follow-up?
The ESsCD says repeat endoscopy may be considered case by case when clinical suspicion is strong27. Coeliac UK, reporting British Society of Gastroenterology advice, describes discussing repeat serology and biopsies 1–2 years after diagnosis, or if new symptoms develop, for someone who keeps eating gluten28.
More in Celiac diagnosis, testing and gluten sensitivity
Reading a celiac biopsy report: Marsh grades and villous atrophyWhat villous atrophy, lymphocyte counts and Marsh 0 to 3c on a celiac biopsy report describe, and why guidelines read them with blood tests.
Follow-up testing after a celiac diagnosis: what the guidelines listWhat celiac guidelines and charities list for follow-up: antibody checks, repeat biopsy, nutrient tests, and what is checked if symptoms continue.
How celiac disease is diagnosed, step by stepFrom blood test to biopsy or no-biopsy diagnosis: what US, European and UK guidelines say, where they differ, and what they say about eating gluten first.
Endoscopy for celiac disease: what to expect on the dayWhat NIDDK, the ACG and celiac charities say about the endoscopy and small intestine biopsy used to diagnose celiac disease, before, during and after.
Diagnosing celiac disease in children without a biopsy: what the ESPGHAN guideline requiresThe conditions ESPGHAN sets for diagnosing celiac disease in a child without a biopsy, what must be confirmed first, and how US guidance differs.
Questions to bring to a gastroenterologist when celiac disease is suspectedQuestions for a celiac disease appointment: what to bring, what the sources say about diet before testing, and what to ask about the biopsy and follow-up.
All 25 guides in Celiac diagnosis, testing and gluten sensitivity
Related guides
Reading a tTG-IgA result: cutoffs, borderline results and lab differencesWhat the number, cutoff and flag on a tTG-IgA report mean, why labs differ, and where guidelines draw the line at 10 times the upper limit of normal.
How a gluten challenge works before celiac testingWhat named celiac sources say about the amount and length of a gluten challenge before testing, side by side, and why a clinician plans it.
Seronegative celiac disease: when antibodies are negative but the biopsy is notWhat seronegative celiac disease means, which checks come before the label (total IgA, gluten intake, other causes) and what published series report.
The repeat biopsy in celiac disease: when guidelines suggest one and what the result meansWhen guidelines suggest a repeat biopsy in celiac disease, what Marsh grades on the report mean, and what the guidelines say follows if damage persists.
Sources
- [1, 4, 10, 14, 20] Gut (BMJ), via PubMed Central, The Oslo definitions for coeliac disease and related terms, checked Nov 17, 2026.
- [2, 3, 5, 6, 15, 16, 17, 18, 21, 22, 23, 24, 25, 26, 27, 43] United European Gastroenterology Journal (European Society for the Study of Coeliac Disease), via PubMed Central, European Society for the Study of Coeliac Disease 2025 Updated Guidelines on the Diagnosis and Management of Coeliac Disease in Adults. Part 1: Diagnostic Approach, checked Nov 17, 2026.
- [7, 8, 33, 40] Gut (BMJ), via PubMed, Clinical outcomes of potential coeliac disease: a systematic review and meta-analysis (Shiha et al., 2024; abstract), checked Nov 17, 2026.
- [9] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Diagnosis of Celiac Disease, checked Nov 17, 2026.
- [11] American Journal of Gastroenterology (American College of Gastroenterology), via PubMed, American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease (abstract), checked Nov 17, 2026.
- [12, 29, 30, 31, 32, 41, 42] Coeliac UK, Testing for Coeliac Disease: Blood Tests and Biopsy, checked Nov 17, 2026.
- [13] Journal of Pediatric Gastroenterology and Nutrition (ESPGHAN guidelines), via PubMed, European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020 (abstract), checked Nov 17, 2026.
- [19, 28] Coeliac UK, How to test adults (healthcare professionals), checked Nov 17, 2026.
- [34, 35] Gastroenterology, via PubMed, Progression of Celiac Disease in Children With Antibodies Against Tissue Transglutaminase and Normal Duodenal Architecture (Auricchio et al., 2019; abstract), checked Nov 17, 2026.
- [36, 37, 38, 39] Clinical Gastroenterology and Hepatology, via PubMed, Features and Progression of Potential Celiac Disease in Adults (Volta et al., 2016; abstract), checked Nov 17, 2026.